Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature
Autore:
Bangalore, N; Bhargava, P; Hawkins, MJ; Bhargava, P;
Indirizzi:
Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Div Hematol Oncol, Washington, DC 20007 USA Georgetown Univ Washington DC USA 20007 l Oncol, Washington, DC 20007 USA Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA GeorgetownUniv Washington DC USA 20007 Pathol, Washington, DC 20007 USA
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 2, volume: 12, anno: 2001,
pagine: 271 - 274
SICI:
0923-7534(200102)12:2<271:SROSRC>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMBINATION CHEMOTHERAPY; DOXORUBICIN; CYCLOPHOSPHAMIDE; DACARBAZINE; IFOSFAMIDE; CANCER;
Keywords:
complete response; doxorubicin-based chemotherapy; MAID; sarcomatoid renal-cell carcinoma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Bhargava, P Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Div Hematol Oncol, Podium B,3800 Reservoir Rd NW, Washington, DC 20007 USA Georgetown Univ Podium B,3800 Reservoir Rd NW Washington DC USA 20007
Citazione:
N. Bangalore et al., "Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature", ANN ONCOL, 12(2), 2001, pp. 271-274

Abstract

The sarcomatoid variant of renal-cell carcinoma (SRCC), a clinically aggressive subtype of renal parenchymal tumors, is typically resistant to systemic treatments and carries a poor prognosis. The authors report a case of a 57-year-old male with advanced SRCC who had a durable complete response after MAID (mesna, adriamycin, ifosfamide and dacarbazine) chemotherapy, and remains free of disease four years after completing treatment. To the authors' knowledge, this is the first report of a remission from MAID chemotherapy in SRCC. A review of published literature revealed occasional responses after systemic chemotherapy. Notably, all responses were seen with doxorubicin containing regimens, suggesting that doxorubicin is a critical componentin chemotherapy regimens for SRCC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 12:41:40